ESSA Pharma Inc (EPI):企業の財務・戦略的SWOT分析

◆英語タイトル:ESSA Pharma Inc (EPI) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH457850FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Essa Pharma Inc (Essa Pharma) is a drug developer that offers oncology therapeutics. The company develops EPI-506, disrupts androgen receptor transcriptional activity through selectively blocking the N-terminal domain of the AR. It also conducts research on prostate cancer and the androgen receptor, metastatic CRPC, and the androgen receptor as a therapeutic target. Essa Pharma’s EPI-506 is used treat medical and surgical therapies that decrease androgen levels. The company has collaboration with the cancer prevention and research institute to advance science for cancer biology developments. It operates in Canada and the US. Essa Pharma is headquartered in Vancouver, British Columbia, Canada

ESSA Pharma Inc Key Recent Developments

Mar 26,2021: ESSA Announces Change to its Board of Directors
Feb 11,2021: ESSA Pharma provides corporate update and reports financial results for fiscal first quarter ended December 31, 2020
Dec 15,2020: ESSA Pharma provides corporate update and reports financial results for fiscal fourth quarter and year ended September 30, 2020
Oct 26,2020: ESSA Pharma announces delisting from the TSX-V
Jun 30,2020: ESSA Pharma provides corporate update and reports financial results for fiscal third quarter ended June 30, 2020

This comprehensive SWOT profile of ESSA Pharma Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ESSA Pharma Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

ESSA Pharma Inc – Key Information
ESSA Pharma Inc – Overview
ESSA Pharma Inc – Key Employees
ESSA Pharma Inc – Key Employee Biographies
ESSA Pharma Inc – Key Operational Heads
ESSA Pharma Inc – Major Products and Services
ESSA Pharma Inc – History
ESSA Pharma Inc – Company Statement
ESSA Pharma Inc – Locations And Subsidiaries
ESSA Pharma Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

ESSA Pharma Inc – Business Description
ESSA Pharma Inc – Corporate Strategy
ESSA Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
ESSA Pharma Inc – Strengths
ESSA Pharma Inc – Weaknesses
ESSA Pharma Inc – Opportunities
ESSA Pharma Inc – Threats
ESSA Pharma Inc – Key Competitors

Section 3 – Company Financial Performance Charts

ESSA Pharma Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

ESSA Pharma Inc, Key Information
ESSA Pharma Inc, Key Ratios
ESSA Pharma Inc, Share Data
ESSA Pharma Inc, Major Products and Services
ESSA Pharma Inc, History
ESSA Pharma Inc, Key Employees
ESSA Pharma Inc, Key Employee Biographies
ESSA Pharma Inc, Key Operational Heads
ESSA Pharma Inc, Other Locations
ESSA Pharma Inc, Subsidiaries
ESSA Pharma Inc, Key Competitors
ESSA Pharma Inc, SWOT Analysis
ESSA Pharma Inc, Ratios based on current share price
ESSA Pharma Inc, Annual Ratios
ESSA Pharma Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ESSA Pharma Inc (EPI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Annexon Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Annexon Inc (Annexon) is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates inclu …
  • Aston Martin Lagonda Global Holdings Plc (AML):企業の財務・戦略的SWOT分析
    Aston Martin Lagonda Global Holdings Plc (AML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Booz Allen Hamilton Holding Corporation (BAH):企業の財務・戦略的SWOT分析
    Booz Allen Hamilton Holding Corporation (BAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Isetan Mitsukoshi Holdings Ltd (3099):企業の財務・戦略的SWOT分析
    Isetan Mitsukoshi Holdings Ltd (3099) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Bangladesh Power Development Board:電力:M&Aディール及び事業提携情報
    Summary Bangladesh Power Development Board (BPDB) is an integrated electric utility. It generates using gas, furnace, diesel, hydro, coal and solar; and imports power from India. The company operates independent power plants /SIPP, rental power plant and REB using steam turbine, gas turbine, combine …
  • Pt Sarihusada Generasi Mahardhika:企業の戦略・SWOT・財務分析
    Pt Sarihusada Generasi Mahardhika - Strategy, SWOT and Corporate Finance Report Summary Pt Sarihusada Generasi Mahardhika - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • SPAR Osterreichische Warenhandels AG:企業の戦略的SWOT分析
    SPAR Osterreichische Warenhandels AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Abivax SA (ABVX)-製薬・医療分野:企業M&A・提携分析
    Summary Abivax SA (Abivax) is a biotechnology company that researches, develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases. The company’s pipeline products comprise ABX464, a small molecule against HIV; ABX311 for chikungunya; ABX544 to …
  • Namibia Breweries Limited:戦略・SWOT・企業財務分析
    Namibia Breweries Limited - Strategy, SWOT and Corporate Finance Report Summary Namibia Breweries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Orchid Pharma Ltd (ORCHIDPHAR):企業の財務・戦略的SWOT分析
    Summary Orchid Pharma Ltd (Orchid), formerly Orchid Chemicals & Pharmaceuticals Ltd is a pharmaceutical company that develops and manufactures pharmaceutical solutions such as formulations and API products. The company offers formulations such as cardiovascular products, neuropsychiatry products, an …
  • Lanco Infratech Ltd:発電所・企業SWOT分析
    Lanco Infratech Ltd – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Karur Vysya Bank Ltd:企業の戦略・SWOT・財務情報
    Karur Vysya Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Karur Vysya Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Warpaint London plc (W7L):企業の財務・戦略的SWOT分析
    Warpaint London plc (W7L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Chiome Bioscience Inc (4583)-製薬・医療分野:企業M&A・提携分析
    Summary Chiome Bioscience Inc (Chiome Bioscience) is a healthcare service company that offers research and development of therapies. The company research and develops antibody drugs for the treatment of autoimmune and inflammatory diseases. Its ADLib system is a monoclonal antibody generating system …
  • InterOil Exploration & Production ASA (IOX):企業の財務・戦略的SWOT分析
    Summary InterOil Exploration & Production ASA (InterOil Exploration & Production) is an oil and gas company that provides petroleum exploration services. The company acquires, explores, develops and operates oil and natural gas properties, among others. It operates as an active license partner in se …
  • Grupa Azoty Zaklady Chemiczne Police SA (PCE):企業の財務・戦略的SWOT分析
    Grupa Azoty Zaklady Chemiczne Police SA (PCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Balt Extrusion SAS:医療機器:M&Aディール及び事業提携情報
    Summary Balt Extrusion SAS (Balt) is a medical technology company which designs, manufactures and markets interventional neuro radiology (INR) devices such as intracerebral microcatheters, extrusion tubes, vascular stents and access systems. Its product portfolio includes magic, a flow-dependant mic …
  • RCI Banque SA:企業の戦略的SWOT分析
    RCI Banque SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Electricity Generating Public Co Ltd (EGCO)-エネルギー分野:企業M&A・提携分析
    Summary Electricity Generating Public Co Ltd (EGCO), a subsidiary of Electricity Generating Authority of Thailand (EGAT), is an energy utility. It produces electricity from natural gas, coal, biomass, waste, hydro, solar, wind, and geothermal sources. Through interests in independent power producer …
  • INTRUST Financial Corporation:企業の戦略・SWOT・財務情報
    INTRUST Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary INTRUST Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆